Tissue and serum levofloxacin concentrations in diabetic foot infection patients

The Journal of Antimicrobial Chemotherapy
K OberdorferH von Baum

Abstract

Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections. The purpose of our study was to determine the serum and tissue concentrations of levofloxacin when administered orally in patients with infected diabetic foot ulcers and to compare these values with microbiological findings. Ten outpatients with diabetes and ulcerations of the lower extremity were included. All patients received oral levofloxacin therapy at a dose of 500 mg once daily. Wound tissue and serum samples were collected and levofloxacin concentrations determined by HPLC with fluorescence detection. Additionally, microbiological cultures were performed from swabs and debrided wound tissue, both before and after treatment. MICs of levofloxacin for all bacterial isolates were determined using the Etest. Following oral treatment with levofloxacin for an average of 10 +/- 3.8 days, all patients received debridement at the affected limbs. The levofloxacin concentrations in necrotic wound tissue were between 2.33-23.23 mg/kg and between 0.12-6.41 mg/L in serum. Tissue-to-serum ratios of levofloxacin concentrations for each patient were >1.0. The MIC values for all ...Continue Reading

References

Oct 1, 1976·Annals of Internal Medicine·T J LouieS L Gorbach
Feb 1, 1997·Clinical Pharmacokinetics·D N Fish, A T Chow
Apr 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B A LipskyR Fernau
May 7, 1999·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·A J BoultonW J Ennis
Mar 29, 2001·Journal of Pharmaceutical and Biomedical Analysis·S BöttcherH G Sonntag
Apr 27, 2002·Journal of Clinical Pharmacy and Therapeutics·A T ChowR R Williams
Jul 30, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald R GrahamCynthia L Fowler
Jan 14, 2004·Emerging Infectious Diseases·Stephen G WeberYehuda Carmeli

❮ Previous
Next ❯

Citations

Oct 21, 2005·Advances in Therapy·Thomas Zgonis, Thomas S Roukis
Sep 28, 2010·European Journal of Clinical Pharmacology·Jolanta Majcher-PeszynskaUNKNOWN Moxifloxacin-DFI Study Group
Aug 25, 2009·Current Infectious Disease Reports·Sandra Bliss Nelson
Dec 15, 2015·Enfermedades infecciosas y microbiología clínica·Silvia Lozano-AlonsoEduardo Ros-Díe
Aug 23, 2011·The International Journal of Lower Extremity Wounds·Marie Clare ZammitGodfrey LaFerla
Feb 3, 2007·Expert Review of Anti-infective Therapy·Philippa C MatthewsBenjamin A Lipsky
Jan 23, 2010·Journal of the American Podiatric Medical Association·David P Nicolau, Gary E Stein
Sep 20, 2019·The International Journal of Lower Extremity Wounds·Prakhar Srivastava, Karthikeyan Sivashanmugam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.